Rosuvastatin calcium

ChemicalBook > CAS DataBase List > Rosuvastatin calcium

Anti-hyperlipidemia drugs Pharmacological effects Pharmacokinetics Drug Interactions Synthesis pathways Indications Safety Side effects Uses

Product Name: Rosuvastatin calcium
CAS No.: 147098-20-2
Chemical Name: Rosuvastatin calcium
Synonyms: CRESTOR;ROSUVASTATIN CA;Rosuvastatin Calcium CRS;Rosuvastatin for system suitability CRS;BD-04;Rostar;S 4522;ZD4522;Fortius;Rosuvastadine
CBNumber: CB9482678
Molecular Formula: C22H30CaFN3O6S
Formula Weight: 523.63
MOL File: 147098-20-2.mol

Less

Rosuvastatin calcium Property

Melting point:: 122°C
alpha: D24 +14.8° (c = 1.012 in 50% methanol)
storage temp.: 2-8°C
solubility: DMSO : 25 mg/mL (49.94 mM; Need ultrasonic)H2O : 1 mg/mL (2.00 mM; Need ultrasonic)
form: powder
color: white to beige
optical activity: [α]/D +12 to +18°, c = 1 in methanol: water (1:1)
λmax: 243nm(Phosphate buffer sol.)(lit.)
Merck: 14,8270
InChIKey: JSVIQRTVYKCCOM-LMRKSJJTNA-N
SMILES: C(/C1=C(N=C(N(C)S(=O)(=O)C)N=C1C1C=CC(F)=CC=1)C(C)C)=C\[C@@H](O)C[C@@H](O)CC(=O)O.[Ca] |&1:24,27,r|
CAS DataBase Reference: 147098-20-2(CAS DataBase Reference)

Less

Safety

RTECS: MJ9675070
HS Code: 29350090

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: 1606015
Product name: Rosuvastatin Calcium
Purity: United States Pharmacopeia (USP) Reference Standard
Packaging: 300MG
Price: $1520
Updated: 2024/03/01

Sigma-Aldrich

Product number: SML1264
Product name: Rosuvastatin calcium
Purity: ≥98% (HPLC)
Packaging: 10MG
Price: $112
Updated: 2023/06/20

Sigma-Aldrich

Product number: Y0001721
Product name: Rosuvastatin for system suitability
Purity: European Pharmacopoeia (EP) Reference Standard
Packaging: Y0001721
Price: $151
Updated: 2023/06/20

Sigma-Aldrich

Product number: SML1264
Product name: Rosuvastatin calcium
Purity: ≥98% (HPLC)
Packaging: 50MG
Price: $451
Updated: 2023/06/20

Sigma-Aldrich

Product number: PHR1928
Product name: Rosuvastatin Calcium
Purity: Pharmaceutical Secondary Standard; Certified Reference Material
Packaging: 1G
Price: $224
Updated: 2022/05/15

Less

Rosuvastatin calcium Chemical Properties,Usage,Production

Anti-hyperlipidemia drugs

Rosuvastatin calcium is an anti-hyperlipidemia drug which belongs to the inhibitor of HMG-CoA reductase successfully developed by the British AstraZeneca company. It is suitable for the treatment of various lipid abnormalities, including hypercholesterolemia, mixed lipid qualitative abnormalities and simple hypertriglyceridemia. Rosuvastatin calcium is listed as the strongest and the most comprehensive statins drugs which has entered into market for lipid-lowering and adjustment. Compared with atorvastatin which is currently recognized with the world's best efficacy, it has a better effect of lowering the level of LDL cholesterol and increasing the level of high-density lipoprotein. Moreover, it has a better tolerance, lower side effects and unique pharmacokinetic characteristics with the half-life about 20h. It only needs to be taken once a day.

Pharmacological effects

Rosuvastatin is a selective inhibitor of HMG-CoA reductase. HMG-CoA reductase inhibitor is the rate-limiting enzyme of the transition hydroxy-3-methylglutaryl coenzyme A to valerate A (The precursor of cholesterol). The main site of action of rosuvastatin is liver-the target organs of cholesterol-lowering. Rosuvastatin increases the number of hepatic LDL receptors on the cell surface, promoting the absorption and catabolism of LDL, inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
For patients of homozygous and heterozygous familial hypercholesterolemia, non-familial hypercholesterolemia, and mixed dyslipidemia, Rosuvastatin can lower the total cholesterol, LDL-C levels, ApoB levels, non-HDL-C levels. Rosuvastatin also reduces the level of TG and increase the level of HDL-C. For patients of pure hypertriglyceridemia, rosuvastatin can lower total cholesterol, LDL-C, VLDL-C, ApoB, non-HDL-C, TG levels and increase the HDL-C levels.
Based on the general safety of pharmacology, repeated dose toxicity, potential genetic toxicity and the clinical information of carcinogenicity, no special toxicity was found for rosuvastatin on the human body. For studies on rat before and after birth, Rosuvastatin has obvious reproductive toxicity. It reduces the size, weight of the litter and birth rate. Treating female rats with a toxic dose which causes several times higher systemic exposure levels than the therapeutic exposure can enable the observation of these phenomena.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Pharmacokinetics

The drug can be absorbed in great amount by liver after oral administration with the volume of distribution at 134 L. After 3~5 hours, plasma concentration reaches the peak. The absolute bioavailability is around 20%. Plasma protein binding rate (mainly albumin) is about 90%. About 90% of the total dose of rosuvastatin is excreted by feces as prototype (including the absorption of the active substance and unabsorbed), with the rest excreted through the urine. 5% rosuvastatin in urine is in the form of prototype. Half-life of plasma elimination is about 19 hours. Elimination half-life doesn’t increase with increased dose. The geometric mean of plasma clearance rate is about 50L/hour (coefficient of variation 21.7%). Same as other HMG-CoA reductase inhibitors, the uptake of rosuvastatin by liver involves the participation of membrane transporter OATP-C. The transporter is important in the liver for the clearance of rosuvastatin.

Drug Interactions

1. Cyclosporine: when this product is used in combination with cyclosporine, the AUC of rosuvastatin is averagely 7 times higher than that observed in healthy volunteers (compared with the same dose using this service). Combination usage does not affect the plasma concentrations of cyclosporine.
2. Vitamin K antagonists: same as other HMG-CoA reductase inhibitor, for patients of simultaneously usage of vitamin K antagonists (such as warfarin), at the beginning or gradually increasing the dose of this product may cause the increase of INR (international normalized ratio). Stop using the product or gradually decreasing the dose can lead to decrease in INR. In this case, appropriate INR testing is needed.
3. Combination of gemfibrozil, fenofibrate, other fibrates and lipid-lowering doses (≥1g/day) of niacin with HMG-CoA reductase inhibitors can increase the risk of myopathy, which may be due to that they can cause myopathy when given alone.
4. Antacids: Mixing the product and one antacid containing aluminum hydroxide and magnesium for suspension can reduce the concentration of statin rosuvastatin plasma by 50%. Taking antacids two hours after taking this can further reduce the impact. The clinical significance of this drug interaction has not been studied.
5. Erythromycin: Combination with erythromycin can cause rosuvastatin AUC (0~t) decrease by 20% and Cmax decrease by 30%. This interaction may be due to the gastrointestinal motility caused by increase of erythromycin.
6. Oral administration of contraceptives/hormone replacement therapy (HRT): while using this drug together with oral contraceptives can cause the increase of ethinyl estradiol and norgestrel AUC by 26% and 34%, respectively. When choosing the dose of oral contraceptives, the patients should consider the increase of the plasma concentration of these drugs. Yet there are no pharmacokinetic data on taking rosuvastatin and HRT together. Therefore, we cannot exclude the presence of similar interactions. However, in clinical trials, this kind of combination is widely applied and can be well tolerated by patients.

Synthesis pathways

Figure 1 Synthesis pathways of Rosuvastatin calcium

Indications

Primary Hypercholesterolemia: Usual dose of rosuvastatin calcium (10 mg) can significantly reduce LDLC levels in patients of primary hypercholesterolemia, and has a better efficacy compared with atorvastatin calcium (10mg). At the end of the experiment, TC, TG levels drop even more. Moreover, 5 mg of rosuvastatin calcium within the same eight weeks of treatment has a better effect on reducing LDLC level compared with 10 mg atorvastatin calcium. The difference is statistically significant, suggesting that the lipid-lowering effect of rosuvastatin calcium is better than that of atorvastatin calcium. Our experimental results are also consistent with the other previous assessment (STELLAR, MERCURY) about efficacy studies on statin drugs. Rosuvastatin calcium has a stronger LDLC-lowering effect than the other statins drugs (atorvastatin, simvastatin and pravastatin), allowing more patients to achieve recommended treatment goals.
Elderly coronary heart disease combined hyperlipidemia: Rosuvastatin calcium is capable of competitively inhibiting liver methylglutaryl coenzyme A reductase, and further exerts its good effect on reducing the fat. It has a long half-life. The gender and age of patients have no significant effect on the metabolism of drugs. The drug has only a few of adverse reactions. Meanwhile, the drug can also effectively promote the transport of low-density lipoprotein into cells, thus improving the cleaning effect of LDL, and playing a role in effectively lowering LDL. In addition, rosuvastatin calcium may also inhibit the aggregation of platelet, reduce the body's inflammatory response and protect their endothelial cells, effectively stabilize the plaque of patients suffering coronary artery disease to reduce its impact on the patient. The patients of experimental group in our hospital were treated with rosuvastatin calcium, which gives a significantly better lipid-lowering effect than patients in the control group, P <0.05, the difference was statistically significant. This further illustrates the usage of rosuvastatin calcium for treatment of elderly coronary heart disease combined hyperlipidemia has a good effect which can improve efficacy, reduce the blood fat with high clinical significance.

Safety

In terms of safety issue, the incidence of adverse cases for rosuvastatin calcium was similar to that of other related drugs. Adverse cases include elevated ALT, increased GGT and nausea.

Side effects

1. Adverse reactions of this product are generally mild and transient such as common headache, dizziness, constipation, nausea, abdominal pain, muscle pain and weakness.
2. For observed patients, the increase of creatine kinase (CK) levels is dose-related; the majority of cases were mild, asymptomatic and transient. Stop the treatment once the CK levels elevate (> 5 × ULN).
3. Impact on the liver: for a small number of patients, it was observed for a drug dose-related increase in transaminases; the majority of cases were mild, asymptomatic and transient.

Uses

For making lipid-lowering drugs.

Description

Rosuvastatin, one of the two new statins launched for the treatment of hypercholesterolemia, has high hepato-selectivity and more potent inhibitory effect on HMG-CoA reductase than the previously marketed statins. In rat hepatocytes, it inhibits cholesterol biosynthesis with an IC₅₀ of 1.12 nM, which is ～100-fold higher potency than pravastatin. Rosuvastatin is synthesized in a 12-step sequence, entailing the construction of a pyrimidinyl aldehyde intermediate in eight steps and subsequent introduction of the dihydroxyheptenoate side chain via Wittig reaction with a bketophosphorane reagent and stereoselective carbonyl reduction of the resultant enone. Pharmacokinetic properties of rosuvastatin in humans, dosed at 5–80 mg, are approximately linear with dose. Following oral administration, rosuvastatin is rapidly absorbed with an oral bioavailability of ～20% and tmax of ～3 h. It has a prolonged duration of action, with terminal t_1/2 of ～20 h, compatible with once-daily dosing. In humans, rosuvastatin is minimally metabolized through CYP2C9 and CYP2C19, with little or no metabolism via the CYP3A4. Approximately 90% of the administered oral dose is eliminated in the feces (92% as the parent compound) and the rest in the urine. Rosuvastatin is considered a “superstatin” due to its ability, at well-tolerated doses, to lower LDL cholesterol and triglycerides to a much greater extent than first generation statins. In patients with hypercholesterolemia, rosuvastatin treatment at doses of 5 and 10 mg/day over 12-week period resulted in 40–43% reduction of LDL-cholesterol levels, 12–13% increase in HDL-cholesterol, and 17– 19% reduction in triglycerides. In comparison, the efficacy range of LDL-cholesterol reductions by atorvastatin (10 mg/day), pravastatin (20 mg/day), and simvastatin (20 mg/day) was 28–35%. Rosuvastatin is a well-tolerated drug at doses of 1–20 mg and the most common side effects at these doses are headache, myalgia, pain and pharyngitis, which are consistent with those previously reported for statin therapy.

Chemical Properties

White to Off-White Crystalline Solid

Originator

Shinogi (Japan)

Uses

Rosuvastatin Calcium Salt is a selective, competitive HMG-CoA reductase inhibitor. Antilipemic.

Uses

antiinflammatory, glucocorticoid

Uses

antirheumatic

Definition

ChEBI: An organic calcium salt that is the hemicalcium salt of rosuvastatin.

brand name

Crestor (AstraZeneca).

General Description

Rosuvastatin calcium (ROS) has a molecular mass of 1001.14. ROS is a member of the "statins" group and is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Biochem/physiol Actions

Rosuvastatin calcium is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin calcium is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Mechanism of action

Rosuvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.24 Rosuvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).44 The overall effect is a decrease in plasma LDL and VLDL.

Synthesis

The synthesis of optically pure rosuvastatin (23) begins from the Knoevenagel reaction of p-fluorobenzaldehyde (193) with ethyl isobutylacetate (194) to give unsaturated ketoester 195. Compound 195 was condensed with (S ) - methylisothiourea and then aromatized in situ using DDQ in methylene chloride to give pyrimidine 196 in 50% yield. Pyrimidine sulfide 196 was then oxided by m-CPBA to give sulfone 197 in 96% yield. Sulfone 197 was reacted with methylamine in methanol followed by treatment with methanesulfonyl chloride to give the N - methanesulfonylamino pyrimidine 198 in 58% yield. Reduction of ester 198 with DIBAL-H followed by TPAP oxidation afforded aldehyde 199 in 58% yield. Aldehyde 199 was subjected to Wittig reaction with optically pure ylide, (3R)-3-(t-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate (200), to give heptenoate compound 201 in 71% yield. Compound 201 was deprotected with HF in acetonitrile, and stereoselective chelation-controlled reduction with Et2BOMe and NaBH4 in THF-MeOH mixed solvent gave methyl (3R, 5S, 6E)- dihydroxyheptenoate 202 in 85% yield. Diol 202 was hydrolyzed with aqueous NaOH to afford the corresponding sodium salt. Rosuvastatin calcium salt (23) was obtained as white powder from the sodium salt on treatment with aqueous CaCl2.

storage

Store at +4°C

Rosuvastatin calcium Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Rosuvastatin calcium Suppliers

Bangladesh 1 Canada 6 China 506 Czech Republic 1 Europe 3 France 2 Germany 6 Greece 1 India 212 Indonesia 2 Israel 1 Italy 1 Japan 3 Mexico 1 Nepal 1 Philippines 1 Poland 1 Singapore 1 Slovenia 4 South Africa 1 South Korea 15 Switzerland 1 The Netherlands 2 United Arab Emirates 1 United Kingdom 23 United States 64 Global 861

JIANGXI AIFEIMU TECHNOLOGY CO.,LTD

Tel: 793-33899567 13735087952
Fax: +86-570-6259526
Email: sales@afmpharm.com
Country: China
ProdList: 91
Advantage: 61

Shandong Loncom Pharmaceutical Co., Ltd.

Tel: 0531-88072380 0531-88116830 13791093792
Email: sales@bestcomm.cn
Country: China
ProdList: 34
Advantage: 58

Shan Dong FengJin Pharmaceutical Co.,Ltd.

Tel: 15898960030
Email: tanxiaohui@fengjin-pharma.com
Country: China
ProdList: 21
Advantage: 58

CHANGZHOU PHARMACEUTICAL FACTORY

Tel: 519-88821493 18915891730
Email: shm@czpharma.com
Country: China
ProdList: 163
Advantage: 58

J & K SCIENTIFIC LTD.

Tel: 010-82848833 400-666-7788
Fax: 86-10-82849933
Email: jkinfo@jkchemical.com
Country: China
ProdList: 96815
Advantage: 76

3B Pharmachem (Wuhan) International Co.,Ltd.

Tel: 821-50328103-801 18930552037
Fax: 86-21-50328109
Email: 3bsc@sina.com
Country: China
ProdList: 15839
Advantage: 69

shilang(zhuoli group)-pharma(nanjing) co.,ltd.

Tel: 86-25-87797880,81,82 -809
Fax: 86-25-85318152
Email: shilang@shilang-pharma.com
Country: China
ProdList: 40
Advantage: 55

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6005
Advantage: 61

TCI (Shanghai) Development Co., Ltd.

Tel: 021-67121386
Fax: 021-67121385
Email: Sales-CN@TCIchemicals.com
Country: China
ProdList: 24529
Advantage: 81

Beijing HwrkChemical Technology Co., Ltd

Tel: 010-89508211 18501085097
Fax: 010-89508210
Email: sales.bj@hwrkchemical.com
Country: China
ProdList: 8418
Advantage: 55

Shijiazhuang Sdyano Fine Chemical Co., Ltd.

Tel: 0311-89250318 031166536426
Fax: 4000311741
Email: master@sjzsdyn.com
Country: China
ProdList: 2963
Advantage: 65

Beijing Ouhe Technology Co., Ltd

Tel: 010-82967028 13552068683
Fax: +86-10-82967029
Email: 2355560935@qq.com
Country: China
ProdList: 12390
Advantage: 60

JinYan Chemicals(ShangHai) Co.,Ltd.

Tel: 13817811078
Fax: 86-021-50426522,50426273
Email: sales@jingyan-chemical.com
Country: China
ProdList: 9976
Advantage: 60

Jia Xing Isenchem Co.,Ltd

Tel: 0573-85285100 18627885956
Fax: 0573-85285100
Email: isenchem@163.com
Country: China
ProdList: 9513
Advantage: 66

Adamas Reagent, Ltd.

Tel: 400-6009262 16621234537
Fax: 021-64823266
Email: chenyj@titansci.com
Country: China
ProdList: 14103
Advantage: 59

Shanghai Longsheng chemical Co.,Ltd.

Tel: 021-58099652-8005 13585536065
Fax: 021-58099609
Email: bin.wu@shlschem.com
Country: China
ProdList: 9809
Advantage: 59

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 19179
Advantage: 64

Shanghai Hanhong Scientific Co.,Ltd.

Tel: 021-54306202 13764082696
Email: info@hanhongsci.com
Country: China
ProdList: 42958
Advantage: 64

Chemsky（shanghai）International Co.,Ltd.

Tel: 021-50135380
Email: shchemsky@sina.com
Country: China
ProdList: 32321
Advantage: 50

XiaoGan ShenYuan ChemPharm co,ltd

Tel: 15527768850
Email: 1791901229@qq.com
Country: China
ProdList: 8836
Advantage: 52

Jinan Trio PharmaTech Co., Ltd.

Tel: +86 (531) 88811783
Fax: +86 (531) 55696010 QQ 1762738062
Email: sales@trio-pharmatech.com (International market)
Country: China
ProdList: 1856
Advantage: 62

PSN Pharmaceutical Technology Co., Ltd.

Tel: 86-25-57062118
Fax: 86-25-57065896
Email: sales@jspsn.com
Country: China
ProdList: 496
Advantage: 57

China Langchem Inc.

Tel: 0086-21-58956006
Fax: 0086-21-58956100
Country: China
ProdList: 7811
Advantage: 57

Tianjin heowns Biochemical Technology Co., Ltd.

Tel: 400 638 7771
Email: sales@heowns.com
Country: China
ProdList: 14435
Advantage: 57

Hunan Hui Bai Shi Biotechnology Co., Ltd.

Tel: 0731-85526065 13308475853
Email: ivy@hnhbsj.com
Country: China
ProdList: 4554
Advantage: 62

Wuhan Fortuna Chemical Co., Ltd

Tel: 027-59207852 13308628970
Fax: QQ3130921841
Email: buy@fortunachem.com
Country: China
ProdList: 2866
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: meilunui@163.com
Country: China
ProdList: 4727
Advantage: 58

BioBioPha Co., Ltd.

Tel: 0871-65217109 13211707573;
Fax: 0871-65215563
Email: y.liu@mail.biobiopha.com
Country: China
ProdList: 5653
Advantage: 65

ShangHai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847 13636370518
Fax: 021-55068248
Email: shyysw007@163.com
Country: China
ProdList: 4940
Advantage: 60

Synthetics China Co.,Ltd

Tel: 0512-65218020; 18261037325
Email: ivy.shen@pharmsyn.com
Country: China
ProdList: 101
Advantage: 60

T&W GROUP

Tel: 021-61551611 13296011611
Fax: ＋86 21-50676805
Email: contact@trustwe.com
Country: China
ProdList: 9895
Advantage: 58

Shanghai civi chemical technology co.,Ltd

Tel: 86-21-34053660
Fax: 86-21-34053661
Email: sale@labgogo.com
Country: China
ProdList: 9865
Advantage: 52

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12335
Advantage: 58

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1493
Advantage: 55

China Kouting Group Limited

Tel: +86 (21) 5811-6473 5811-6475
Fax: +86 (21) 6129-4103
Email: sales@koutingchina.com
Country: China
ProdList: 496
Advantage: 60

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 400-400-6206333 18521732826
Fax: 021-50323701
Email: market@aladdin-e.com
Country: China
ProdList: 25003
Advantage: 65

VOT INTERNATIONAL BUSINESS CO.,LTD

Tel: 0536-2456718
Fax: 0536-8231856
Country: China
ProdList: 226
Advantage: 55

Suizhou HongQi Chemical Corporation Limited

Tel: 0722-3257376 13026100080
Fax: 0722-3257381
Email: 774811011@qq.com
Country: China
ProdList: 64
Advantage: 55

Bsisun HK Imoprt And Export Company Limited

Tel: +86-18068513926
Fax: 0086-519-85153711
Country: China
ProdList: 1277
Advantage: 55

China Nobel Chem Co., Limited

Tel: +86(0)21 60484900
Fax: +86(0)21 60484900
Country: China
ProdList: 764
Advantage: 50

Cantotech Chemicals, Ltd.

Tel: 86-0755-86635001
Fax: 86-0755-22642228
Email: cantotech@126.com
Country: China
ProdList: 4566
Advantage: 55

Shanghai Raise Chemical Technology Co.,Ltd

Tel: +86-021-50935922
Fax: +86-021-33847795
Country: China
ProdList: 7865
Advantage: 55

Guangzhou Isun Pharmaceutical Co., Ltd

Tel: 020-39119399 18927568969
Fax: 020-39119999
Email: isunpharm@qq.com
Country: China
ProdList: 4674
Advantage: 55

Nanjing Sunlida Biological Technology Co., Ltd.

Tel: 025-57798810
Fax: 025-57019371
Email: sales@sunlidabio.com
Country: China
ProdList: 3239
Advantage: 55

TargetMol Chemicals Inc.

Tel: 021-021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7783
Advantage: 58

Cato Research Chemicals Inc.

Tel: 020-81960175
Fax: +1-541-2553641
Email: min.he@cato-chem.com
Country: China
ProdList: 1955
Advantage: 55

Hubei XinyuanShun Chemical Co., Ltd.

Tel: 13971561712, 13995564702, 027-50664929
Fax: 027-50664927
Email: hbeixys2001@163.com
Country: China
ProdList: 3120
Advantage: 55

Shanghai JONLN Reagent Co., Ltd.

Tel: 400-0066400 13621662912
Fax: 021-55660885
Email: 422131432@qq.com
Country: China
ProdList: 9978
Advantage: 55

Changzhou EFC Chemistry&Science Co.,Ltd

Tel: 18136598690 18136597130
Fax: 86-0519-89617886
Country: China
ProdList: 235
Advantage: 58

Less

View Lastest Price from Rosuvastatin calcium manufacturers

Sinoway Industrial co., ltd.

Product: Rosuvastatin Calcium 147098-20-2
Price: US $0.00-0.00/Kg/Bag
Min. Order: 1Kg/Bag
Purity: EP / GMP
Supply Ability: 20 tons
Release date: 2024-06-27

WUHAN FORTUNA CHEMICAL CO., LTD

Product: Rosuvastatin calcium 147098-20-2
Price: US $0.00-0.00/Kg/Drum
Min. Order: 1KG
Purity: 98%-102%
Supply Ability: 100KGS
Release date: 2021-07-23

Nanjing Fred Technology Co., Ltd

Product: Rosuvastatin calcium 147098-20-2
Price: US $0.00-0.00/kg
Min. Order: 1kg
Purity: 99%, Single impurity＜0.1
Supply Ability: 1 ton
Release date: 2024-01-04

147098-20-2, Rosuvastatin calciumRelated Search:

Calcium carbonate Thiophanate-methyl Tribenuron methyl Calcium carbide Calcium citrate Isopropyl alcohol 2,2-Bis(hydroxymethyl)propionic acid Calcium chloride Methyl salicylate Methanesulfonamide p-Toluenesulfonamide Pitavastatin calcium ISOPROPYL LAURATE Kresoxim-methyl Calcium Propionate Sulfanilamide Simvastatin Methyl acetate

6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)-

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl])-3,5-dihydroxyhept-6-enoic acid hemicalcium salt

Rosuvastatin Calcium(W.S)

ZD 4522 Calcium

ROSUVASTATIN CALCIUM (ROSUVASTATIN HEMICALCIUM)

Rosuvastadine

Rosuvastatin CalciuM (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-Methylethyl)-2-[N-Methyl(n-Methylsulfonyl)aMino]-5-pyriMidinyl]-3,5-dihydroxy-6-Heptenoic calciuM

Rosuvastatin Calium

Fortius

Rostar

Rosuvastatin hemicalcium

S 4522

ZD 4522, Calcium Salt

Rosuvastain Calcium

rosuvastatin Rosuvastatin CalciuM

(3R,5R,6E)-7-[4-(4-fluorophenyl)-2-(N-MethylMethanesulfonaMido)-6-(propan-2-yl)pyriMidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

(+)-(3R,5S)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-Methyl-N-MethanesulfonylaMino)pyriMidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid calciuM salt (2:1)

Rosuvastatin calciuM(Crestor)

Rosuvastatin CalciuM (AMorphous)

Rosuvastatin CalciuM (ForM A)

BD-04

(3R,5S,6E)-7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid calcium salt

Rosuvastatin calcium Solution, 100ppm

(+)-bis[7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3R,5S-dihydroxy-6(E)-heptenoic acid]calcium salt

calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethan-3-ylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

ZD4522

(3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[N-methyl(n-methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-Hep

Rosuvastatin (as Ca salt)

ROSUVASTATIN, CALCIUM SALT

ROSUVASTATIN CALCIUM

ROSUVASTATIN CA

Calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-y

CRESTOR

(3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[N-methyl(n-methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-Heptenoic calcium

RosuvastatinCalcium&Z7,Z8,R3

7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid

Rosuvastatin for system suitability CRS

RosuvastatinCalcium&gt

Rosuvastatin Calcium CRS

Rosuvastatin Impurity 116

Rosuvastatin CaL

Rosuvastatin for system suitability

Calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Rosuvastatin calcium USP/EP/BP

Rosuvastatin Calcium，Rusuvastatin Calcium

(3R,5S,6E)-7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid

Rosuvastatin S-Isomer

Rosuvastatin-d3 Calcium Salt

Rosuvastatin Calcium (Y0001719)

Rosuvastatin calciumQ: What is Rosuvastatin calcium Q: What is the CAS Number of Rosuvastatin calcium Q: What is the storage condition of Rosuvastatin calcium Q: What are the applications of Rosuvastatin calcium

Rosuvastatin for system suitability (Y0001721)

Rosuvastatin Calcium (1606015)

(+/-)-Fargesin

(E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate

Rosuvastatin Calcium Salt CRS

Rosuvastatin Calcium (3R,5S,6E)-7-{4-(4-Fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5- dihydroxyhept-6-enoic acid calcium salt

Rosuvastatin Calcium (BP)

(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid, calcium salt